Parkinson's disease and RLS: the dopaminergic bridge

被引:74
|
作者
Rye, DB [1 ]
机构
[1] Emory Univ, Sch Med, Program Sleep Med, Atlanta, GA 30322 USA
关键词
restless legs syndrome; dopamine; Parkinson's disease;
D O I
10.1016/j.sleep.2004.01.016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dopamine is a neurotransmitter that modulates diverse waking behaviors including movement, motivation, cognition, reward, and feeding Interest in dopamine's additional contributions to normal and pathologic sleep-wake states has experienced a recent rebirth originating from two clinical disorders: Parkinson's disease and Restless Legs Syndrome. The former, the prototypical disorder of brain dopamine cell loss, is accompanied by marked sleep disruption and impairments in daytime alertness. The latter is exquisitively responsive to pharmacologic agents that act upon dopamine receptors. The potential neurobiological substrates underlying these observations are reviewed here. Converging lines of evidence suggest that mesocorticolimbic dopamine circuits are involved in promoting wakefulness, while a less studied diencephalospinal dopamine system might underly the sensorimotor dysfunction of Restless Legs Syndrome. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:317 / 328
页数:12
相关论文
共 50 条
  • [21] Continuous dopaminergic delivery in Parkinson's disease
    Antonini, Angelo
    Ursino, Giulia
    Calandrella, Daniela
    Bernardi, Laura
    Plebani, Mauro
    JOURNAL OF NEUROLOGY, 2010, 257 : S305 - S308
  • [22] Dopaminergic Therapy in Parkinson's Disease: An Update
    Cristobal, Gurutz Linazasoro
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 5 - 6
  • [23] Existing dopaminergic therapies for Parkinson's disease
    Dutta, Aloke K.
    Le, Weidong
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (12) : 1613 - 1625
  • [24] Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
    Mamelak, Mortimer
    NEUROLOGY AND THERAPY, 2018, 7 (01) : 5 - 11
  • [25] Delusion and dopaminergic systems in Parkinson's disease: A comparison study with hallucination in Parkinson's disease
    Lee, E
    Chung, SJ
    Sung, YH
    Kim, SR
    Lim, JH
    Lee, MJ
    MOVEMENT DISORDERS, 2006, 21 : S101 - S101
  • [26] Modeling of Parkinson's disease by damaging dopaminergic neurons
    Toshpulatova, L.
    Kulmanova, M.
    MOVEMENT DISORDERS, 2019, 34 : S300 - S300
  • [27] Parkinson's disease severity and use of dopaminergic medications
    Fang, John Y.
    Perez, Adriana
    Christine, Chadwick W.
    Leehey, Maureen
    Aminoff, Michael J.
    Boyd, James T.
    Morgan, John C.
    Dhall, Rohit
    Nicholas, Anthony P.
    Bodis-Wollner, Ivan
    Zweig, Richard M.
    Goudreau, John L.
    PARKINSONISM & RELATED DISORDERS, 2015, 21 (03) : 297 - 299
  • [28] Dopaminergic modulation of emotional memory in Parkinson’s disease
    Thomas D. Hälbig
    Ute A. Kopp
    Franziska Wodarz
    Joan C. Borod
    Jean-Michel Gracies
    Georg Ebersbach
    Andreas Kupsch
    Journal of Neural Transmission, 2008, 115 : 1159 - 1163
  • [29] Dopaminergic modulation of prospective memory in Parkinson's disease
    Costa, Alberto
    Peppe, Antonella
    Brusa, Livia
    Caltagirone, Carlo
    Gatto, Ilaria
    Carlesimo, Giovanni Augusto
    BEHAVIOURAL NEUROLOGY, 2008, 19 (1-2) : 45 - 48
  • [30] Dopaminergic modulation of motor coordinaton in Parkinson's disease
    Park, Jaebum
    Lewis, Mechelle M.
    Huang, Xuemei
    Latash, Mark L.
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (01) : 64 - 68